Blue Jet Healthcare Limited — Q3 FY26 earnings call

Call held 13 Feb 2026

Management summary

Blue Jet Healthcare reported a challenging Q3 FY26 with significant YoY declines in revenue, EBITDA, and PAT, primarily due to destocking, supply chain realignment, and lower sales volumes impacting operating leverage. However, the company is making substantial strategic investments in a Vizag Greenfield project (Rs.1,000 crores), Hyderabad R&D expansion (Rs.40 crores), and Unit 3 capacity expansion, with management expressing strong confidence in FY27 growth driven by new product launches and capacity qualifications.

Highlights

  • Vizag Greenfield project, with a Rs.1,000 crores investment, is set to be a pivotal growth platform for API and intermediates.

  • Hyderabad R&D expansion (Rs.40 crores) will strengthen innovation pipeline and technical capabilities, focusing on emerging technologies.

  • Unit 3 expansion is nearing completion and expected to be ready for qualification in Q1 FY27, playing a key role in de-bottlenecking the supply chain.

  • Company is initiating exhibit batches for a new artificial sweetener in FY27, addressing a growing segment of global demand.

  • PAT doubled from Rs.160 crores in FY24 to Rs.300 crores in FY25, demonstrating strong historical profit growth.

  • 70% of power consumption is met through wind and solar, and the company received the National Award for Excellence in Energy Management.

Concerns

  • Revenue from operations decreased by 40% YoY to Rs.192.4 crores in Q3 FY26.

  • EBITDA decreased by 62% YoY and 15% QoQ in Q3 FY26, with EBITDA margin at 24%.

  • PAT decreased by 39% YoY and 23% QoQ in Q3 FY26.

  • Gross margin for Q3 was 52%, slightly lower than normal trend, due to change in product mix and a one-time write-off of inventory.

  • EBITDA was impacted by operating leverage from lower sales volume, labor code implementation, and engagement of foreign consultants.

  • Destocking and supply chain realignment for the flagship PI/API product is impacting current orders, expected to take a couple of quarters to realign.

Key financials

3 periods

Headline

  • Revenue from Operations
    ₹192.4 Cr
    YoY -40% QoQ +16%
  • EBITDA Margin
    24%
    YoY -62% QoQ -15%
  • PAT Growth
    —
    YoY -39% QoQ -23%

Q3

  • Gross Margin
    52%

9M

  • Revenue Growth
    —
    YoY +3%
  • EBITDA Growth
    —
    YoY -6%
  • PAT Growth
    —
    YoY -6%
  • Gross Margin
    53%
  • Other Income
    ₹4.5 Cr

What they filed

Q1 FY27: revenue down 17.5%, net profit down 14.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue208 318 340 355 165 −21%192 −40%235 −31%293 −17%
EBITDA69 124 140 121 55 −20%47 −62%71 −49%98 −19%
Net profit58 99 110 91 52 −10%40 −60%64 −42%78 −14%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Capex ₹1,000 Cr
    • Vizag Greenfield project for API and intermediates capacity ₹1,000 Cr
    • Hyderabad R&D center for emerging technologies ₹40 Cr
    • Unit 3 expansion for contrast media intermediates (cumulative to date) ₹146 Cr
    This project was approved by a board with a total investment plan of Rs.1,000 crores over the next three to four years. The initial capacities under development are aligned with customer demand and long-term business visibility. (Shiven Arora) As a part of our next phase, we are investing about Rs.40 crores to build a new R&D center at Hyderabad (V. K. Singh) Our expansion project is nearing completion... and we have incurred a cumulative CAPEX of approximately Rs.146 crores to-date. (Shiven Arora)
  • Debt Debt disclosed
    Right now, we have Rs.410 crores cash as of December... So, for us, being a debt-free company, we have all options available. (Ganesh Karuppannan)
  • Liquidity Cash ₹410 Cr Company is debt-free and has various options for funding future CAPEX, including internal accruals, debt market, and capital market.
    Right now, we have Rs.410 crores cash as of December. We will continue to use internal accrual for the initial phase of CAPEX. We have both opportunities open. We could actually tap the debt market or we could also like use the capital market... So, for us, being a debt-free company, we have all options available. (Ganesh Karuppannan)

Guidance & targets

Capex

  • Vizag Greenfield Project Investment Capex · next 3-4 years · High confidence Rs.1,000 crores
    I think as per the board approval, we have committed a CAPEX of Rs.1,000 crores over the next three to four years.

    — Shiven Arora

  • Hyderabad R&D Center Investment Capex · next phase · High confidence Rs.40 crores
    As a part of our next phase, we are investing about Rs.40 crores to build a new R&D center at Hyderabad

    — V. K. Singh

Capacity

  • Unit 3 Qualification Readiness Capacity · Q1 '27 · High confidence Ready for qualification
    It is expected to be ready for qualification in Q1 '27.

    — Shiven Arora

Product Pipeline

  • New Artificial Sweetener Exhibit Batches Product Pipeline · FY27 · High confidence Initiating exhibit batches
    As a part of our focus on specialty ingredients, we are initiating a few exhibit batches of the new artificial sweetener in FY27.

    — Shiven Arora

  • Late Stage Assets (PI/API) Kicking In Product Pipeline · about two years from now · Medium confidence 6 assets
    So, the late stage assets are about six. And I think they will start kicking in about two years from now.

    — VK Singh

  • New Sweetener Target Capacity/Market Potential Product Pipeline · between FY27 and FY28 · Medium confidence 10% or $1 billion
    I think in terms of the target capacity that we are targeting is about 10% or $1 billion.

    — Shiven Arora

Margin

  • Gross Margin Band Margin · ongoing · Medium confidence 50% to 55%
    It should be between 50% to 55% depending on the product mix.

    — Sanjay Sinha

Product Launch

  • Iodinated Contrast Media Commercial Launch Product Launch · FY27, ramp-up from Q1 itself · High confidence Commercial launch and ramp-up
    So in FY27, you will see the commercial launch. And the ramp-up will happen from Q1 itself, is our understanding.

    — V. K. Singh

What to watch in Q4 FY26

PI/API product volume recovery

next quarter
Current Subdued due to destocking/realignment
Target Volumes coming back, orders normalizing

Why it matters

This is a flagship product, and its recovery is key to overall revenue growth and normalization of financial performance.

our assessment is that it might take a couple of quarters for this to get completely realigned... We are still very bullish on this product. We do not see any concern or issue.

Risks & concerns

  • Channel inventory de-stocking and supply chain realignment for PI/API

    medium

    Subdued orders for PI/API due to channel inventory and supply chain changes, expected to realign in a couple of quarters.

    Management acknowledged

  • Gross margin compression due to product mix and one-time inventory write-off

    medium

    Q3 gross margin at 52% (vs 65% in Q2, 53% YTD) due to product mix change and 1% impact from one-time inventory write-off of old stock.

    Management acknowledged

  • Lower sales volume impacting EBITDA margin

    medium

    EBITDA margin at 24% in Q3, lower due to operating leverage from reduced sales, labor code costs, and recurring foreign consultant expenses.

    Management acknowledged

  • Delayed validation for iodinated contrast media

    low

    Validation for iodinated contrast media took longer than expected, but management remains positive about its FY27 outlook.

    Management acknowledged

Q&A highlights

7 direct
Destocking impact and recovery timeline for PI/API product Direct
See, there is clearly some channel inventory for which there is some de-stocking happening. But at the same time, there is a supply chain realignment that is also happening... our assessment is that it might take a couple of quarters for this to get completely realigned.

Addresses the primary reason for subdued orders in the flagship product and provides a timeline for potential normalization, crucial for future revenue outlook.

Asked by Amlan Das

Contrast media segment launches, contribution, and market share sustainability Direct
Typically, in contrast media, there were two needle movers for us. One is an advanced intermediate for the existing product that we make, which is currently under validation... And the second molecule is the NCE intermediate, which has done well for us in the past 12- months... The growth outlook in these two molecules is extremely encouraging... These are very sticky relations. And in most of these cases, these are backed by multi-year supply agreements.

Clarifies the specific growth drivers within the contrast media segment and reassures investors about the stability and long-term nature of these customer relationships.

Asked by Amlan Das

Gross margin volatility, impact of product mix and inventory write-off Direct
If you see gross margin on a YTD basis is around 53% compared to 55% last financial year. So, it is only a difference of 2%, out of which roughly 1% impact is on certain inventory write-offs, which are old stock, which was sitting in our inventory. 1% impact is there. And balance 1% is basically a swing because of product mix... Now that, whatever overhead which gets inventorized actually gets released into this quarter, when you actually like book the revenue, that is how the accounting works. So, to that extent, you would actually see a slight dip in the gross margin.

Provides a detailed explanation for the lower gross margin in Q3, attributing it to a one-time inventory write-off and accounting effects from goods in transit, clarifying that the underlying YTD margin is more stable.

Asked by Sanjesh Jain

Supply chain realignment for Bempedoic acid and its benefit to Blue Jet Partial
Sanjesh, I think it is a little premature on our part to comment on it. But all that I can say is that it will work in our favor. And it is not that supplies from Blue Jet are not going and somebody else is supplying. Or the end molecule is doing well. So it is neither the case. So I think it is just about some realignment and channel de-stocking.

Highlights an ongoing strategic realignment for a key product, with management expressing confidence in a positive outcome for Blue Jet despite not providing specific details.

Asked by Sanjesh Jain

Confidence for FY27 revenue growth and margin recovery given subdued FY26 Direct
And the two major lines that we have created one, for the cardiovascular molecule and the other one, was for the NCE intermediate on contrast media. Both of them would be positively contributing for FY27, which is backed by some customer orders... The third incremental aspect would be the backward integration play for the contrast media intermediates in Unit-III... And the fourth one is the iodinated contrast media, which the validation took longer than expected. But, the forecasts are very encouraging. And this keeps us very positive in terms of the FY27 outlook.

Management provides a comprehensive explanation for their positive FY27 outlook, linking it to specific capacity additions, new product contributions, and backward integration benefits.

Asked by Sanjesh Jain

Funding strategy for the Rs.1,000 crores Vizag CAPEX program Direct
Right now, we have Rs.410 crores cash as of December. We will continue to use internal accrual for the initial phase of CAPEX. We have both opportunities open. We could actually tap the debt market or we could also like use the capital market... So, for us, being a debt-free company, we have all options available.

Clarifies how the company plans to finance its significant Vizag CAPEX, emphasizing its strong liquidity position and debt-free status, which provides flexibility.

Asked by Andy

Impact of foreign consultant engagement on EBITDA and its recurring nature Direct
This would be a recurring expense. And it is more strategic in nature... These are all European-based consultants who will be helping the company in strategizing and transforming. They will add a lot of value to the idea.

Explains a specific recurring cost impacting EBITDA, clarifying its strategic purpose for company transformation and value addition.

Asked by Shyam Sampat

Commercialization timeline, realizations, and volumes for the iodinated contrast media product Direct
So in FY27, you will see the commercial launch. And the ramp-up will happen from Q1 itself, is our understanding. The value per Kg, it would be higher than our main molecule because it is a forward integration thing.

Provides clear timelines for the commercial launch and ramp-up of a new, high-value product, indicating its potential to contribute significantly to future revenue.

Asked by Avneesh Burman

3 min read 7 chapters

Detailed narrative

Vizag Greenfield Project Update

Blue Jet Healthcare announced that the groundbreaking ceremony for its Vizag project is scheduled for this month. This Greenfield site is envisioned as a pivotal growth platform, with Phase-1 dedicated to API and intermediates for new products aligned with customer requirements. The board has approved a total investment plan of Rs.1,000 crores over the next three to four years, with initial capacities aligned to customer demand. Management believes the scale, infrastructure, and geographic advantage of Vizag will strengthen its positioning as a reliable global partner in complex chemistries.

R&D Expansion and Innovation Pipeline

The company has secured lease space for R&D activities in Hyderabad, with development work expected to commence from Q3 FY27. This expansion involves an investment of approximately Rs.40 crores and aims to strengthen the innovation pipeline and technical capabilities. The focus areas include emerging technologies, intermediates for GLP-1s, peptide chemistry, and bio-catalysis. Blue Jet is currently tracking around 20 active RFPs, including six high-conviction phase-3 programs and two commercial products.

Artificial Sweetener Pipeline Development

As part of its focus on specialty ingredients, Blue Jet Healthcare is initiating a few exhibit batches of a new artificial sweetener in FY27. This new product is expected to complement the existing high-intensity sweetener portfolio and address a growing segment of global demand. Management indicated that the target capacity or market potential for this new sweetener is about 10% or $1 billion, with key milestones expected between FY27 and FY28.

Unit 3 CAPEX and Operational Progress

The expansion project at Mahad Unit-3, which focuses on backward integration into contrast media intermediates, is nearing completion. This facility, designed for a key side chain in the contrast media portfolio, incorporates robust safety, environmental, and automation systems. It has incurred a cumulative CAPEX of approximately Rs.146 crores to-date and is expected to be ready for qualification in Q1 FY27. This unit is anticipated to play a crucial role in de-bottlenecking the supply chain and supporting future growth.

Financial Performance Overview (Q3 & 9M FY26)

For Q3 FY26, Blue Jet Healthcare reported a 40% YoY decrease in revenue from operations to Rs.192.4 crores, though it saw a 16% QoQ increase. EBITDA declined by 62% YoY and 15% QoQ, resulting in a 24% EBITDA margin. PAT also decreased by 39% YoY and 23% QoQ. The gross margin for Q3 was 52%, attributed to a change in product mix and a one-time inventory write-off. For the nine months ended December 31, 2025, revenue from operations increased by 3% YoY, while EBITDA and PAT both decreased by 6% YoY, with a gross margin of 53% compared to 50% last year.

Destocking and Supply Chain Dynamics

Management acknowledged that the subdued orders for its flagship PI/API product are due to channel inventory de-stocking and supply chain realignment. They estimate that it might take a couple of quarters for the situation to get completely realigned. Despite this, they remain 'very bullish' on the product, noting its end molecule is showing good mid-level two-digit growth and opening up in new markets like Japan. The company expects volumes to revive soon, supported by binding forecasts and confirmed purchase orders.

Sustainability and Operational Excellence

Blue Jet Healthcare continues to integrate sustainability into its operations, with 70% of its power consumption now met through wind and solar sources. The company emphasizes atom efficiency in synthetic chemistry and sustainable process design, having recently been recognized with the National Award for Excellence in Energy Management by CII. Furthermore, a dedicated process excellence department has been established, supported by strong additions in engineering, quality, and supply chain to enhance reliability and responsiveness.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls